March 25, 2020 / 12:45 PM / 10 days ago

BRIEF-Biosig Subsidiary Neuroclear Acquires License For A Broad-Spectrum Anti-Viral Agent That May Treat COVID-19

March 25 (Reuters) - Biosig Technologies Inc:

* BIOSIG SUBSIDIARY NEUROCLEAR ACQUIRES LICENSE FOR A BROAD-SPECTRUM ANTI-VIRAL AGENT THAT MAY TREAT COVID-19. LABORATORY RESULTS DEMONSTRATE HIGH LEVEL OF ACTIVITY AGAINST COVID-19 IN CELL CULTURE

* BIOSIG TECHNOLOGIES INC - INTENDS TO PURSUE DEVELOPMENT OF AGENT FOR TREATMENT OF COVID-19 THROUGH FDA-APPROVED CLINICAL TRIALS.

* BIOSIG TECHNOLOGIES INC - EXPECTS THAT VICROMAX(TM) COULD BE USED ALONE OR IN A COMBINATION WITH OTHER ANTI-VIRAL AGENTS OR IMMUNE MODULATORS

* BIOSIG - ORALLY ADMINISTERED, BROAD-SPECTRUM ANTI-VIRAL AGENT VICROMAX DEMONSTRATED STRONG ACTIVITY AGAINST COVID-19 IN CELL CULTURES IN LAB TESTING

* BIOSIG TECHNOLOGIES INC - APPOINTED NICK SPRING AS CEO OF VIRALCLEAR AND STEVE KING AS COO

* BIOSIG TECHNOLOGIES INC - VICROMAX WAS ADDED TO A TISSUE CULTURE ASSAY FOR SARS-CO-2 CORONAVIRUS AND AN ANTI-VIRAL EFFECT WAS OBSERVED

* BIOSIG TECHNOLOGIES - INTENDS TO DEVELOP VICROMAX AND TAKE IT THROUGH CLINICAL TRIALS UNDER A NEW NEUROCLEAR SUBSIDIARY, VIRALCLEAR PHARMACEUTICALS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below